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Abstract 
Pharmacological and genetic rodent models of schizophrenia play an important role in the drug 
discovery pipeline, but quantifying the molecular similarity of such models with the underlying 
human pathophysiology has proved difficult. We developed a novel systems biology methodology 
for the direct comparison of anterior prefrontal cortex tissue from four established glutamatergic 
rodent models and schizophrenia patients, enabling the evaluation of which model displays the 
greatest similarity to schizophrenia across different pathophysiological characteristics of the disease. 
Liquid chromatography coupled tandem mass spectrometry (LC-MSE) proteomic profiling was 
applied comparing healthy and “disease state” in human post-mortem samples and rodent brain 
tissue samples derived from models based on acute and chronic phencyclidine (PCP) treatment, 
ketamine treatment or NMDA receptor knockdown. Protein-protein interaction networks were 
constructed from significant abundance changes and enrichment analyses enabled the identification 
of five functional domains of the disease such as “development and differentiation”, which were 
represented across all four rodent models and were thus subsequently used for cross-species 
comparison. Kernel-based machine learning techniques quantified that the chronic PCP model 
represented schizophrenia brain changes most closely for four of these functional domains. 
This is the first study aiming to quantify which rodent model recapitulates the neuropathological 
features of schizophrenia most closely, providing an indication of face validity as well as potential 
guidance in the refinement of construct and predictive validity. The methodology and findings 
presented here support recent efforts to overcome translational hurdles of preclinical psychiatric 
research by associating functional dimensions of behaviour with distinct biological processes. 
Keywords 
schizophrenia; systems biology; psychosis models; molecular validity; chronic phencyclidine 
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1. Introduction 
Schizophrenia (SCZ) affects approximately 1% of the world’s population and has been listed as one of 
the top ten causes of disease-related disabilities in the world (Rössler et al., 2005; “WHO | The 
global burden of disease: 2004 update,”). Antipsychotics represent the first line of pharmacotherapy 
for SCZ and predominantly target dopamine, noradrenaline and serotonin pathways (Tandon et al., 
2008). However these medications typically fail to treat the cognitive and  negative symptoms, which 
contribute substantially to the morbidity of SCZ (Buchanan and Gold, 1996; Green, 1996; Greenwood 
et al., 2005). Due to increased evidence that dysfunction of glutamatergic transmission is implicated 
in psychotic states (Konradi and Heckers, 2003; Olney and Farber, 1995; Tsai and Coyle, 2002), 
glutamatergic animal models of the disease have increasingly been used to test the potential efficacy 
of novel compounds (Bondi et al., 2012).     
Glutamatergic mechanisms were initially implicated in SCZ pathogenesis after reduced cerebrospinal 
fluid levels were reported in patients (Kim et al., 1980), with later studies pointing to more complex 
mechanisms behind dysfunction of glutamate neurotransmission (Javitt and Zukin, 1991). 
Glutamatergic models of SCZ in animals include genetic manipulation of the N-methyl-D-aspartate 
(NMDA) receptor (NMDAR) (Halene et al., 2009) and acute or chronic exposure to NMDAR 
antagonists such as phencyclidine (PCP) (Jentsch and Roth, 1999) and ketamine (Kapur and Seeman, 
2002). Systemic treatment with these antagonists in preclinical studies was found to mimic negative 
symptoms of the disease alongside an increase in glutamate efflux in the prefrontal cortex (Liu and 
Moghaddam, 1995; Moghaddam et al., 1997). Administration of PCP and ketamine in clinical studies 
was found to induce psychotomimetic effects ranging from positive symptoms such as hallucinations 
and paranoia (Javitt and Zukin, 1991) to negative and cognitive symptoms in healthy volunteers 
(Grayson et al., 2014; Neill et al., 2014), in addition to precipitating psychotic relapses in chronic 
stable SCZ patients (Lahti et al., 1995).    
 Preclinical evaluation is an important step in the drug discovery pipeline and allows the 
prioritization of compounds for clinical trials. Regardless of ongoing advances in other areas of 
medicine, the development of preclinical models for neuropsychiatric disorders is at a near standstill 
(Nestler and Hyman, 2010a). Additionally, there have been failures in finding new pharmacological 
treatments because the observed outcomes in behavioural screenings were not predictive of clinical 
outcomes. The main reason for this is the fact that uniquely human behavioural symptoms cannot 
be reliably or convincingly mirrored or assessed in animals, explaining difficulties in face validity. On 
the other hand pharmacological validity actually selects for models based on the mechanisms of 
actions of already known compounds. Finally, the face validity of genetic and pharmacological 
models has been criticized as more than a single gene is considered to be important in the etiology 
of SCZ and injections of compounds only induce transient phenotypes. Notwithstanding these 
challenges, there are now attempts to identify molecular disease hallmarks of distinct 
endophenotypes in neuropsychiatric animal models, as an essential stage of their integration into 
the drug development pipeline (Nestler and Hyman, 2010a). 
 Rodents are the most common animal model used,normally coming from a breeding background 
with low heterogeneity and have the potential for highly controlled experimental settings with the 
added benefit of providing a source of freshly collected cerebral tissue samples (Turck et al., 2005).  
Although it is difficult or even impossible to mirror the entire symptom spectrum of a psychiatric 
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disorder in a given animal model, insights into molecular endophenotypes have yielded important 
information into the underlying pathophysiology (Kendler and Neale, 2010). Such models enable the 
study of central biological processes associated with a particular group of symptoms and the testing 
and evaluation of novel treatments. In this study four established rodent models of SCZ based on 
either psychosis-inducing NMDAR-antagonists (Ketamine and PCP) or genetic modifications targeting 
the glutamate system (NR1-knockdown) were investigated. Rats were chosen over mice in the 
pharmacological models to increase brain tissue yield for proteomic extractions. Mice were chosen 
for the NR1 knockdown due to the availability of superior methods of genetic manipulation 
compared to rats.Here, we have integrated the proteomic information of human SCZ post mortem 
brains and four rodent models of the disease in a novel systems biology approach. The anterior 
frontal cortex was chosen as the tissue of interest in both humans and rodents as a brain region 
which is strongly linked to psychotic disorders. The anterior prefrontal cortex plays a crucial role in 
the processing and evaluation of internally generated information across multiple cognitive 
operations (Ramnani and Owen, 2004). The negative and cognitive symptoms of schizophrenia are 
characterized by impairments in executive functioning and socio-emotional cognition.  
The biological processes affected in the anterior frontal cortices in each condition were 
characterized and compared across species and models. Based on protein-protein-interaction 
networks we identified key functional patterns that allowed us to quantify the molecular similarity of 
the models with the human condition, introducing a novel way to interrogate translational 
preclinical validity. 
2. Materials and Methods 
Figure 1 provides a step by step illustration of the methodology behind this analysis. 
2.1. Clinical Samples 
46 post-mortem anterior prefrontal cortex (BA10) brain samples were obtained from the Stanley 
Medical Research Institute (Torrey et al., 2000). Samples were derived from 23 SCZ patients and 23 
control (CT) subjects. 
Tissue collection took place with full informed consent of a first-degree relative to comply with the 
Declaration of Helsinki. As outlined previously (Gottschalk et al., 2014), there were no differences in 
grey and white matter volumes between samples, and no significant differences in brain side, 
gender or secondary axis diagnosis of alcohol abuse/dependency and drug abuse/dependency 
between patients and controls.    
Four glutamatergic animal models of SCZ commonly used in preclinical drug discovery and 
development were generated applying the protocols outlined below. Rats (Rattus norvegicus) were 
used for the ketamine, acute PCP (aPCP) and chronic PCP (cPCP) models and mice (Mus musculus) 
were used for the NR1 knockdown model. All animals were housed 4-5 per cage on a 12-h light/dark 
cycle in a temperature-controlled facility with food and water available ad libitum. At the end of 
each protocol, rodents were sacrificed (n=X to Y, per group) by decapitation, and brain tissue 
samples were collected. A matching number of control samples were collected at the same time. 
Ketamine:  0.9% sterile saline (n=10) and 10mg/kg ketamine (n=10) injections were administered 
subcutaneously as described previously (Wesseling et al., 2015b). Dosage levels were based on 
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previous research which examined dose/response levels based on locomotor activity ataxia, brain 
dialysis/neurotransmitter release and pharmacological magnetic resonance data (Gastambide et al., 
2013; Li et al., 2014; Littlewood et al., 2006; Smith et al., 2011). Doses were chosen which yielded 
robust readouts while avoiding inducing anaesthesia. Sacrifice and tissue collection took place two 
hours after the last injection.   
aPCP:  A subcutaneous dose of saline (n=10) or 5mg/kg PCP hydrochloride (n  = 10) was 
administered as previously described (Ernst et al., 2012; Palmowski et al., 2014). Sacrifice and tissue 
collection took place 30min after the last injection.  
cPCP: Subcutaneous doses of saline (n=10) or 5mg/kg PCP hydrochloride (n  = 9) were administered 
for 15 consecutive days as previously described (Wesseling et al., 2015c). Sacrifice and tissue 
collection took place 30min after the last injection on day 15.  NR1 Knockdown: NR1 transgenic mice 
were bred and genotyped as previously described (Halene et al., 2009; Mohn et al., 1999; Wesseling 
et al., 2014). 12 adult male homozygous mice and 12 wild-type littermates were used for this study.  
2.2. Label-Free LC-MSE Analysis of Brain Tissue 
Using previously defined storage, preparation and measurement procedures (Gottschalk et al., 
2014), brain samples were analyzed individually in technical duplicates using label-free LC-MSE. For 
the subsequent analysis, a human proteome database was obtained from UniProt (retrieved 2015-
14-10, number of entries 20,196). A joint Mus musculus and Rattus norvegicus database was created 
by merging the protein sequences of the respective UniProt reference proteome files (retrieved 
2015-14-10, number of entries 24,664). MS raw data and ProteinLynx Global Server v2.5 search 
results were imported into the Rosetta Elucidator software (build 3.3, Rosetta Biosoftware). Settings 
and procedures were applied as stated previously (Gottschalk et al., 2014), and peptide signal 
intensities for each sample were exported for pre-processing and statistical analysis in R (R 
Development Core Team, 2013). Only peptides with an amino acid sequence ending in R or K were 
considered to avoid unspecific trypsin cleavage. Non-unique peptides were excluded. Sample 
outliers were identified using the first two principal components (Beniger et al., 1980) resulting in 
the removal of one control sample from the aPCP, cPCP, Ketamine and NR1-knockdown models. 
Following log2 transformation to stabilize data variance, protein abundance changes for the human 
and rodent model comparisons were determined using a linear model, with a stepwise selection 
adjustment for covariates age, gender, diagnoses of alcohol or substance abuse, post-mortem 
interval (PMI), brain pH and brain side. We analyzed the data using a fixed effects linear model and 
allowed for the duplicate measurements using a robust variance estimator (Freedman, 2006). 
For the SCZ tissue, the false discovery rate (FDR) was controlled at a cut-off of 0.05 by adjusting the 
p-values according to the Benjamini Hochberg procedure (Benjamini and Hochberg, 1995). Due to 
the small sample sizes for each rodent model, a null distribution was empirically generated to obtain 
the actual distribution of p-values (Ernst, 2004). This was done by comparing the ranking of a test 
statistic from the original model to those obtained through 10,000 random permutations of the 
sample status. 
2.3. Protein-Protein Interaction (PPI) Networks 
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An analysis framework was designed to compare SCZ and rodent tissue on a functional level, based 
on the annotation of Gene Ontology (GO) terms to the protein abundance changes described earlier. 
In order for these terms to represent the biophysical interactions which occur between sets of 
proteins (Stelzl et al., 2005), PPI networks for SCZ and the aPCP, cPCP, ketamine and NR1 knockdown 
rodent models were created using the software package Cytoscape v3.2.1 (Cline et al., 2007). Each 
network was represented as a graph where the nodes are proteins and the edges are interactions 
between proteins.  
Networks were constructed by retrieving all available known PPI information for proteins with 
significantly changed abundances following multiple testing or permutations as described in 2.2, and 
their first-order protein interactors, from the databases MINT (Zanzoni et al., 2002), IntAct 
(Hermjakob et al., 2004) and UniProt (Apweiler et al., 2004). Filtering was applied to both the node 
and edge lists for all four networks. Nodes were filtered by taxonomy identifiers (9606 for Homo 
sapiens in the SCZ network, in addition to 10116 and 10090 for Rattus norvegicus and Mus musculus 
respectively in the rodent networks), while edges were filtered to exclude all connections other than 
direct interactions or physical associations between proteins. All unconnected subsets of nodes were 
removed from the network. The structures of each network were assessed using four common 
properties of complex networks, clustering coefficient, average degree, characteristic path length 
and density.  
2.3.1. GO term enrichment  
GO term enrichment was computed on each PPI network using the ClueGO (Bindea et al., 2009) 
Cytoscape package, with default settings unless described below. The ontology category used was 
“Biological Process”. The Homo sapiens GO database was used for the terms of the SCZ network. The 
Mus musculus database was used to evaluate all rodent networks to reduce a species-specific 
annotation bias. A two-sided hypergeometric distribution was used to compute the statistical 
significance of each GO term, describing the probabilities associated with sampling randomly 
without replacement from a finite network of proteins where all proteins have an equal chance of 
being drawn. This determines whether any GO terms occur at a frequency greater than would be 
expected by chance. For each term, p-values were corrected for multiple testing (q-values) by 
applying a Benjamini-Hochberg correction. Terms with a significant q value (q <0.05) were taken 
forward and terms with no significant enrichment (q > 0.05) or less than two proteins were removed 
automatically. 
2.3.2. Kappa Score Grouping 
The list of terms for each network were functionally grouped based on shared underlying proteins 
using a kappa score (Huang et al., 2007) of 0.7. The kappa score metric reflects the degree of the 
relationship between two GO terms. A score of 0.7 or higher requires abundant shared proteins 
(Bindea et al., 2009; Merico et al., 2010), ensuring that the groups are likely to be biologically similar. 
Functional groups which did not contain at least two GO terms were excluded from the analysis. 
Groups were named according to the most significant (q-value <= 0.05) GO term. 
2.3.3 Local Linear Embedding Kernel Group Augmentation 
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The biological interpretation of each functional group was enhanced by augmenting the groups with 
closely related GO terms using a diffusion-type manifold embedding technique called a Local Linear 
Embedding (LLE) kernel, commonly used to group related proteins or genes (Li et al., 2010; Zare et 
al., 2011). Kernels are manifold embedding techniques which are commonly used in bioinformatics 
to classify data points into particular categories (Lerman and Shakhnovich, 2007). In this instance, 
kernel methods are used to compute similarity metrics through a geometric interpretation of 
manifold embedding where each GO term is treated as though positioned in a virtual two-
dimensional space based on its place in the GO tree. The LLE kernel was chosen over other kernel 
techniques, as it emphasizes short-range interactions between terms (Roweis and Saul, 2000). For 
every term in a given functional group, a positive similarity value between that term and any other 
term in the GO database meant this new term was related and could be added to the group. A 
negative value meant that the new term was unrelated.       
 For each SCZ term, the LLE kernel was used to compute the pairwise similarity metric to every other 
term in the Homo sapiens GO tree. Likewise with each aPCP, cPCP, ketamine and NR1-knockdown 
term, similarity metrics were computed to every term in the Mus musculus GO tree. The concept 
behind the use of the LLE kernel to augment the existing functional groups is that the particular 
proteins underlying these additional terms will be associated with a variety of related biological 
functions to those already conveyed by the group. Hence, this method yields more informative 
functional groups of highly related terms.   
2.4. Functional Comparison between SCZ and Rodent Models 
The enhanced groups of GO terms were used as the basis for a functional comparison between SCZ 
and the four rodent models. The percentage overlap of terms in terms of Z score was computed 
between each of the SCZ groups and the rodent model groups. Hierarchical clustering using Ward’s 
criterion was employed to identify related clusters of groups for both SCZ and each model, enabling 
the identification of different functional domains in the disease represented across all four models, 
where each domain is a vector of GO terms. The subsets of GO terms behind each domain which are 
completely unique to that domain were then identified, thus defining the biological functionality 
more precisely.  
2.5. Domain Comparison Through GO Term Similarity 
Having identified a series of unique functional domains of human SCZ represented by the four 
models, it was necessary to quantify which model represented each domain most closely. This was 
done by modifying an approach from genetic research (Fröhlich et al., 2006; Speer et al., 2005) to 
obtain a numerical quantification for the closeness of the models to the disease by computing a 
similarity score between rodent and human domains. These scores were obtained through 
evaluating the average of the best matching GO term similarity between the domain vectors, where 
the pairwise similarity scores between GO terms were obtained using the LLE kernel described in 
2.3.3. The closer the similarity scores between rodent and human domains are to 1, the more similar 
they are, while the closer the scores are to 0, the more dissimilar they are. 
3. Results 
3.1. Behavioural Characteristics of Rodent Models 
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For both acute and chronic models, PCP doses were found to induce the expected abnormalities of 
hyperlocomotion, increased stereotypic behaviour and impaired attention and social interaction as 
reported previously (Lee et al., 2005; Sams-Dodd, 1996). Ketamine doses induced hyperlocomotion, 
stereotypy, impaired information processing with abnormalities in cognitive function, and impaired 
social interaction, behavioural characterizations which has been described in previous acute 
ketamine models (Becker et al., 2003; Gastambide et al., 2013). NR1-knockdown mice displayed 
both hyperlocomotion and increased stereotypic behaviour in addition to impairments in cognition 
and escape behaviours as found previously (Dzirasa et al., 2009).   3.2. Protein Abundance Changes 
for Brain Tissue Comparisons 
A total of 1280 quantifiable proteins were measured across all SCZ brain samples, 643 across all 
aPCP samples, 873 across all cPCP samples, 772 across all Ketamine samples and 409 across all NR1 
knockdown samples. Supplementary Figure 1  summarizes the overlap in proteins measured 
between these groups. Based on linear modelling, we found that 159 proteins were differentially 
expressed in SCZ patients compared to CT individuals, following false discovery correction. Linear 
modelling of the rodent models found 47 proteins to be differently expressed in the aPCP-control 
comparison, 84 in the cPCP-control comparison, 93 in the Ketamine-control comparison and 80 in 
the NR1 knockdown-control comparison, following permutation testing. (Supplementary Tables S1-
S5 display these proteins and their fold changes).  
3.3. PPI Networks and GO Term Enrichment Analysis   
PPI networks were created for SCZ and all four rodent models by PPI information from the UniProt, 
MINT and IntAct protein databases between the significant proteins identified in 3.2, and their 
respective first-order interactors. The significantly changed abundances of these proteins was 
determined through multiple hypotheses testing (human samples) or permutation testing (rodent 
samples).  All rodent model PPI networks, as well as the SCZ PPI network were characterised using 
several structural properties of complex networks – clustering coefficient, average degree, 
characteristic path length and density (Table 1).  
Table 1. Structural properties of PPI Networks  
Condition/
Model 
N n (% of N)  Number of 
nodes 
Number of 
edges 
Clustering 
coefficient 
Average 
degree 
Characteristic 
path length 
Density 
SCZ 159 115 (72%) 2163 3297 0.009 2.698 4.162 0.001 
aPCP 48 29 (62%) 150 203 0.002 2.493 3.772 0.017 
cPCP 85 59 (69%) 351 507 0.017 2.741 3.3 0.008 
Ketamine 94 54 (57%) 189 271 0.039 2.698 4.278 0.014 
NR1knockd
own 
81 52 (64%) 349 537 0.019 2.951 3.368 0.008 
 Abbreviations: SCZ, schizophrenia; aPCP, acute phencycline; cPCP, chronic phencycline; N = number of significant 
proteins, n = number of significant proteins included in the network  
 
The structural properties of average degree and characteristic path length are most closely related 
between the SCZ and Ketamine networks. The cPCP network displays the greatest tendency to form 
clusters to the disease network, indicating that this model has the greatest functional similarities to 
the disease.  Functional enrichment analysis of the networks, and grouping of the resulting terms 
8 
 
according to a Kappa score of 0.7, yielded 222 SCZ functional groups, 63 aPCP groups, 128 cPCP 
groups, 117 Ketamine groups and 119 NR1-knockdown groups, with each group corresponding to a 
specific biological process.  Table 2 displays the top 5 functional groups for SCZ and each rodent 
model, in order of significance.   
 
Table 2. Top 5 functional groups for each PPI Network 
Condition/ 
Model 
N Top five group names No of GO 
terms 
Group p-value No of significant 
proteins per group 
SCZ 2163 Regulation of phosphorus metabolic process 
Phosphorylation 
Protein phosphorylation 
Cellular protein metabolic process 
Intracellular signal transduction 
14 
12 
4 
4 
3 
 
4.7 E-115 
6.4 E-92 
1.1 E-70 
6.2 E-68 
2.1 E-67 
24 
23 
38 
40 
30 
aPCP 150 Cellular component assembly 
Transport 
Regulation of cellular metabolic process 
Negative regulation of biological process 
Regulation of signalling 
3 
3 
23 
2 
4 
1.2 E-16 
4.0 E-15 
4.2 E-15 
5.3 E-14 
6.4 E-14        
6 
14 
14 
7 
4 
cPCP 351 Phosphorus metabolic process 
Organic substance catabolic process 
Single-organism catabolic process 
Transport 
Cell projection organization  
2 
3 
23 
2 
15 
1.6 E-40 
2.4 E-40 
3.2 E-40 
2.2 E-32 
1.7 E-25 
31 
30 
31 
33 
21 
Ketamine 189 Transport 
Regulation of localization 
Cell communication 
Cell-cell signalling 
Regulation of cell communication 
2 
2 
2 
2 
4 
1.4 E-26 
2.3 E-20 
2.7 E-19 
5.1 E-19 
5.2 E-19 
20 
10 
 22 
 6 
 13 
NR1knockd
own 
349 Phosphorus metabolic process 
Transport 
Establishment of localization in cell 
Cellular component assembly 
Regulation of transport 
2 
2 
9 
3 
2 
3.5 E-34 
1.3 E-31 
3.4 E-23 
1.7 E-22 
6.0 E-22 
28 
21 
14 
15 
13 
 
3.4. Identification of Corresponding Functional Domains Between SCZ and Rodent Models 
Following the enhancement of these functional groups by kernel techniques, the percentage overlap 
was computed between SCZ and rodent model groups. It was found that groups which clustered 
together and overlapped are involved in closely related biological processes, resulting in the 
identification of five functional domains of the disease – “development and differentiation”, 
“intracellular signalling and regulation”, “intracellular transport and organization”, “biosynthetic 
processes and energy metabolism”, and “nucleic acid metabolism and ATP/GTPase activity” - which 
are represented across all four models. These domains are shown in Figure 2.  
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PPI network edges for the significant proteins underlying these domains, as identified in 3.2, are 
listed in Supplementary Tables S6-S10. 
3.5. Identification of Most Representative Rodent Model via Similarity Based Methods  
Similarity-based methods were used to compare the vectors of GO terms for each domain, making it 
possible to quantify the model that is most representative of SCZ through similarity scores (Table 3).   
Table 3. Domain Comparison to SCZ Based on Similarity Scores Computed From Feature Space 
Embedding 
Functional Domain aPCP cPCP Ketamine       NR1 
Knockdown 
Development and differentiation 0.398 0.561 0.405 0.445 
Intracellular signalling and regulation 0.365 0.385 0.454 0.396 
Intracellular transport and organization 0.639 0.688 0.644 0.496 
Biosynthetic processes and energy metabolism 0.582 0.61 0.573 0.554 
Nucleic acid metabolism and ATP/GTPase activity 0.68 0.681 0.648 0.658 
  
These scores indicate that overall the cPCP model represents SCZ the most closely for the four 
functional domains, “development and differentiation”, “intracellular transport and organization”, 
“biosynthetic processes and energy metabolism”, and “nucleic acid metabolism and ATP/GTPase 
activity,” more than the other three models. The Ketamine model represents “intracellular signalling 
and regulation” most closely, although the similarity scores between models and the disease were 
generally not so close for this domain (less than 0.5). 
4. Discussion Our current understanding of the underlying molecular pathology associated with SCZ 
is limited. Post-mortem studies and animal models of the disease can provide new insights into the 
patterns of alterations at the genetic and protein level which play a role in the neuropathology of 
SCZ (Chan et al., 2014; Gottschalk et al., 2014; Mäki et al., 2005). However, so far it has proven hard 
to quantify the molecular similarity of the models with the human disease pathology (Nestler and 
Hyman, 2010b). These characterization issues have meant that progress has been limited in 
developing new pharmacotherapies from animal studies (Fonio et al., 2012). As a consequence, few 
new chemical entities have reached the clinic over the last decades.   
In the present study we employed a non-hypothesis driven integration of proteomic data on the 
systems biology level, a methodology which enables the direct comparison of brain changes from 
four rodent models with those observed in human disease brains. This makes it possible to evaluate 
which of the given models represents SCZ most closely for different pathophysiological aspects of 
the disorder. Previous approaches have tried to establish various phenotypic similarities between 
animal models and SCZ through construct, face and predictive validity, assessments predominantly 
based on behavioural paradigms often supplemented with histological or electrophysiological 
investigations (Nestler and Hyman, 2010b). However, these approaches have struggled to establish a 
particular model as the ‘best for use’ for a particular aspect of the disease because assessing 
similarities between animal behaviour and patient characteristics is typically vague, leading to 
difficulties regarding bias and irreproducibility (Tordjman et al., 2007). In addition, demonstrating 
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that molecular changes in SCZ blood serum or plasma alone are equivalent to that of a relevant 
animal model has proven to be challenging (Kluge et al., 2011).      
Hence, rather than relying on a comparison based solely on the significantly altered proteins as 
measured through LCMSE, this method seeks to compare both human and animal tissue at a 
functional level using GO terms annotated to proteins. Conducting a proteomic analysis through the 
construction of protein-protein interaction networks has advantages over a genomic/transcriptomic 
based approach, as this provides a greater indication of the functional alterations within tissue 
(Bayés and Grant, 2009). Additionally, while the heritability of schizophrenia has been approximated 
as being between 50% and 90% based on twin studies, the genetic landscape may not be the best 
framework for comparison as SCZ appears to be a polygenic disorder with disease phenotypes 
arising through the accumulation of multiple small risk genes (Kendler and Diehl, 1993; Maier, 2008; 
Sullivan et al., 2003). A protein-protein interaction network based approach was chosen over 
pathway analysis to characterize the biological processes more precisely through the inclusion of 
first-degree interactors in these networks. Once functional groups had been determined within the 
network, an approach commonly used to compare gene functionality was adopted (Huang et al., 
2012; Plaisier et al., 2012; Poos et al., 2013). This approach utilized kernel methods, one of the most 
advanced techniques in machine learning, to compare vectors of GO terms through their closeness 
to each other in the GO hyperspace, thus making individual comparisons possible between models 
and the disease (Lerman and Shakhnovich, 2007; Schlicker et al., 2006).     
Collectively, this method enabled the identification of five functional aspects identified in SCZ post-
mortem brain tissue which are represented across all four animal models –intracellular signalling 
and regulation, development and differentiation, intracellular transport and localization, 
biosynthetic processes and energy metabolism, nucleic acid metabolism and ATP/GTPase activity. 
Our approach revealed that the latter four functional domains are represented most closely by the 
cPCP model. Blocking the NMDA receptor through PCP treatment has been previously associated 
with neurodegenerative pathologies in both humans and animal models (Lei et al., 2008), but while 
acute NMDA antagonist treatment has mainly been linked to disinhibition of the cortical 
transmitters glutamate, dopamine and serotonin (5-HT) (Adams and Moghaddam, 1998; López-Gil et 
al., 2007), chronic NMDA antagonist administration is associated with more complex molecular and 
behavioural adaptations, leading to a more defined cognitive deficit profile (Jentsch, 1997; Olney et 
al., 1989). This could explain why the cPCP model outperforms the ketamine and aPCP models across 
most categories. Reduced rates of oxygen uptake into mitochondria isolated from brain tissue have 
been observed in previous PCP rat studies, hence it is not unexpected that chronic PCP treatment 
represented impairments in energy metabolism, a common trait of psychiatric diseases (Konradi et 
al., 2004; Prabakaran et al., 2004; Rajasekaran et al., 2015). The significantly changed protein sets 
which underlie each of these functional domains in the chronic PCP model could form the basis of 
future assays for drug development using techniques such as selective reaction monitoring (SRM). 
Once such candidate biomarkers have been identified, SRM can be applied to analyze protein 
abundance levels of these markers in tissue in a quantitative manner.  We have previously reported 
on this in a study of anterior prefrontal cortex tissue from patients with SCZ, bipolar disorder and 
major depressive disorder, in which the expression levels were quantified for a panel of 56 proteins 
suggested to be associated with various functional aspects of these disorders , including for 
examplealterations in cellular energy metabolism and dysfunction of neuronal differentiation 
(Wesseling et al., 2015a). It is interesting to note that despite precautions of introducing a species-
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specific bias (e.g. joint rodent protein database, one shared functional annotation pool) the NR1 
knockdown mice showed the lowest similarity scores across the domains. Although all rodent 
models investigated in this study support the theory of a dysfunctional hypoglutamatergic frontal 
cortex state in SCZ post mortem brains (Gottschalk et al., 2015) we cannot exclude the possibility 
that compensatory developmental mechanisms following a single gene knockdown are more likely 
to influence and potentially dilute a functional cross-species similarity, than the molecular reaction 
of the frontal cortex to NMDA-receptor antagonist exposure in adult animals. 
From a systems biological perspective, this study has several strengths including the use of carefully 
matched post-mortem brain samples while adjusting for covariates in a regression analysis via a 
stepwise selection procedure which accounted for the most commonly addressed confounders while 
avoiding overparameterization. The present approach involved the use of a joint rodent protein 
database at the LCMSE processing stage and the Mus musculus GO database at the GO term 
enrichment stage to avoid introducing any species-specific bias which could bias the results in favour 
of one particular model. The chosen systemic methodology is superior to the standard way of 
pathway analysis based on individual proteins which is most commonly used in preclinical studies. A 
systems approach leverages the signature proteins as a representation of changes in signalling 
pathways, instead of interpreting the relevance between each protein and phenotype. By tackling a 
pressing question in translational research through the adaptation and application of machine 
learning based methods already established as a means of conducting functional comparisons in 
other disciplines of medicine, decision processes in preclinical neuropsychiatry could benefit of 
synergies between different fields of molecular research. While the study did not account for 
directionality in terms of protein signalling, and the effects on a particular function/process can 
differ depending on whether the proteins associated with a particular GO term are 
up/downregulated, there is as yet no standard annotation to account for this in PPI networks. In 
addition, one has to keep in mind that ultimately the identified domains were limited by the 
detected fraction of the proteome and therefore are less likely to contain GO terms based on 
proteins that are difficult to detect in whole-tissue approaches, for example membrane-integral 
proteins or proteins with very specific expression time windows (e.g. proteins involved in apoptosis 
signalling). An identification of domains of "underrepresented" GO terms (inversed enrichment 
analysis) was beyond the scope of this article. 
 The current consensus regarding animal models of psychiatric disorders is that no single model can 
completely recapitulate the full complexity of human conditions (Wong and Josselyn, 2015). As an 
example, auditory electrophysiological abnormalities recorded in studies involving the NR1 
knockdown model are thought to more closely resemble those seen in autism than schizophrenia 
(Gandal et al., 2012). Conversely, this model is a good proxy for behavioural phenotypes which 
invoke some of the negative symptoms of schizophrenia such as impairments in spatial cognitive 
performance (Dzirasa et al., 2009) and reduced social interaction. Hence, it is felt that future models 
of SCZ should be focused on behavioural endophenotypes and more importantly molecular 
alterations, as we gain more understanding of the genetic and neurodevelopmental causes (Powell 
and Miyakawa, 2006; Stewart and Kalueff, 2015). In particular given the failures of current 
medications in treatment of negative and cognitive symptoms of SCZ, preclinical models for different 
symptom clusters are likely to play an increasingly important role in new pharmacological 
approaches (Keefe et al., 2007; Sarnyai et al., 2011; Tomasik et al., 2015, 2014). Our results provide 
evidence that different models can represent functional aspects of SCZ more closely than others, 
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however future research should aim to introduce proteomic information of different putative SCZ 
animal models, most notably dopaminergic manipulations using direct and indirect dopamine 
agonists which have previously shown to induce behavioural phenotypes associated with positive 
and negative symptoms of SCZ such as hyperactivity, persisting prepulse inhibition abnormalities and 
attention deficit (Jones et al., 2011). The flexible structure of the proposed framework allows the re-
evaluation of cross-species network comparisons once new information is available. The presented 
analysis is the first to directly compare multiple animal models to SCZ on a functional level, with the 
findings supporting the notion that a variety of available models, each reflecting different 
pathological molecular hallmarks of SCZ, could be important for insights into the molecular and 
cellular basis of behavioural abnormalities relevant to SCZ, as well as testing their responsiveness to 
existing and upcoming medication. This need will become increasingly important as we seek to reach 
a broader understanding of the ramifications of a given genetic, environmental or pharmacological 
manipulation in the context of psychotic spectrum disorders. 
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